Top

Pediatric Radiology

Published in:

01-10-2012 | Original Article

Marrow signal changes observed in follow-up whole-body MRI studies in children and young adults with neurofibromatosis type 1 treated with imatinib mesylate (Gleevec) for plexiform neurofibromas

Authors: Boaz Karmazyn, Mervyn D. Cohen, Samuel Gregory Jennings, Kent A. Robertson

Published in: Pediatric Radiology | Issue 10/2012

Abstract

Background

We observed bone marrow signal changes (BMSC) in patients with plexiform neurofibromas after treatment with imatinib mesylate (Gleevec).

Objective

To evaluate the pattern and natural history of BMSC.

Materials and methods

The data were obtained from a pilot study of imatinib mesylate in patients with plexiform neurofibromas. All patients underwent baseline and sequential whole-body STIR 1.5-T MRI after treatment. The bone marrow signal on MRI was evaluated for abnormalities, location and pattern, and any change on follow-up studies.

Results

The study group included 16 patients (8 males) with a median age of 14 years (range 4 to 25 years). The mean whole-body MRI follow-up duration was 1.9 years. Of the 16 patients, 14 (88%) developed BMSC. The signal change was asymmetrical in 9 of the 14 patients (64%). The appendicular skeleton was involved in all 14 patients and the axial skeleton in 3 patients (21%). BMSC was followed in 13 patients and decreased signal was seen in 9 patients (69%) after a mean duration of 1.3 years of treatment (range 0.6 to 2.9 years); no complications were observed.

Conclusion

BMSC appeared in most patients with neurofibromatosis type 1 following treatment with imatinib mesylate. BMSC was unusually asymmetrical and involved the lower extremities. On follow-up, BMSC often showed a decrease without complications.

Borthakur G, Cortes JE (2004) Imatinib mesylate in the treatment of chronic myelogenous leukemia. Int J Hematol 79:411–419PubMedCrossRef

Siddiqui MA, Scott LJ (2007) Imatinib: a review of its use in the management of gastrointestinal stromal tumours. Drugs 67:805–820PubMedCrossRef

Jett K, Friedman JM (2010) Clinical and genetic aspects of neurofibromatosis 1. Genet Med 12:1–11PubMedCrossRef

Zoller ME, Rembeck B, Oden A et al (1997) Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer 79:2125–2131PubMedCrossRef

Evans DG, Baser ME, McGaughran J et al (2002) Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 39:311–314PubMedCrossRef

Yang FC, Ingram DA, Chen S et al (2008) Nf1-dependent tumors require a microenvironment containing Nf1+/– and c-kit-dependent bone marrow. Cell 135:437–448PubMedCrossRef

Demestre M, Herzberg J, Holtkamp N et al (2010) Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model. J Neurooncol 98:11–19PubMedCrossRef

McClelland CM, Harocopos GJ, Custer PL (2010) Periorbital edema secondary to imatinib mesylate. Clin Ophthalmol 4:427–431PubMedCrossRef

Larson JS, Bergstrom LK, Cameron JD et al (2007) Severe periorbital edema secondary to imatinib mesylate for chronic myelogenous leukemia. Arch Ophthalmol 125:985–986PubMedCrossRef

10.

Esmaeli B, Prieto VG, Butler CE et al (2002) Severe periorbital edema secondary to STI571 (Gleevec). Cancer 95:881–887PubMedCrossRef

11.

Valeyrie L, Bastuji-Garin S, Revuz J et al (2003) Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 48:201–206PubMedCrossRef

12.

Kelly K, Swords R, Mahalingam D et al (2009) Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Target Oncol 4:99–105PubMedCrossRef

13.

Vanel D, Bonvalot S, Pechoux CL et al (2007) Imatinib-induced bone marrow necrosis detected on MRI examination and mimicking bone metastases. Skeletal Radiol 36:895–898PubMedCrossRef

14.

Tamura T, Tasaka T, Fujimoto M et al (2004) Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy. Haematologica 89:109–110

15.

Berman E, Nicolaides M, Maki RG et al (2006) Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 354:2006–2013PubMedCrossRef

16.

Pietras K, Ostman A, Sjoquist M et al (2001) Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 61:2929–2934PubMed

17.

Bankier AA, Levine D, Halpern EF et al (2010) Consensus interpretation in imaging research: is there a better way? Radiology 257:14–17PubMedCrossRef

Title: Marrow signal changes observed in follow-up whole-body MRI studies in children and young adults with neurofibromatosis type 1 treated with imatinib mesylate (Gleevec) for plexiform neurofibromas
Authors: Boaz Karmazyn
Mervyn D. Cohen
Samuel Gregory Jennings
Kent A. Robertson
Publication date: 01-10-2012
Publisher: Springer-Verlag
Published in: Pediatric Radiology / Issue 10/2012
Print ISSN: 0301-0449
Electronic ISSN: 1432-1998
DOI: https://doi.org/10.1007/s00247-012-2440-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Marrow signal changes observed in follow-up whole-body MRI studies in children and young adults with neurofibromatosis type 1 treated with imatinib mesylate (Gleevec) for plexiform neurofibromas

Abstract

Background

Objective

Materials and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objective

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2012

Hermes

Periventricular nodular heterotopia is related to severity of the hindbrain deformity in Chiari II malformation

The impact of preparation and support procedures for children with sickle cell disease undergoing MRI

Abnormal MIBG uptake in a neuroblastoma patient with right upper lobe atelectasis

Professor Lailai Gu (1938–2011)

ESPR Uroradiology Task Force and ESUR Paediatric Working Group—Imaging recommendations in paediatric uroradiology, Part V: childhood cystic kidney disease, childhood renal transplantation and contrast-enhanced ultrasonography in children